The Potential Role of DUXA as A Drug Target and Biomarker (G503835)

Target Name: DUXA

NCBI ID: G503835

DUXA

Other Name(s): Double homeobox A | DUXA_HUMAN | double homeobox A | Double homeobox protein A

The Potential Role of DUXA as A Drug Target and Biomarker

The double homeobox (DUXA) gene is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. DUXA is a member of the homeobox gene family, which is known for the production of genes involved in cell signaling and development.

DUXA is expressed in a variety of tissues and cells throughout the body, including the brain, heart, and gastrointestinal tract. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DUXA as a drug target

DUXA has been identified as a potential drug target due to its involvement in several diseases. One of the main reasons for its potential as a drug target is its involvement in cancer development. DUXA has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer.

In addition to its involvement in cancer, DUXA has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms of these diseases.

DUXA has also been shown to be involved in autoimmune disorders, such as rheumatoid arthritis and type 1 diabetes. These disorders are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage.

DUXA as a biomarker

In addition to its potential as a drug target, DUXA has also been shown to be a potential biomarker for several diseases. The ability of DUXA to be expressed and processed by the immune system makes it an attractive candidate for use as a biomarker for cancer and other diseases.

DUXA has been shown to be expressed in several types of cancer, including breast, ovarian, and colorectal cancer. This suggests that it could be used as a biomarker for these cancers. In addition, DUXA has also been shown to be expressed in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that it could be used as a biomarker for these conditions as well.

DUXA has also been shown to be expressed in autoimmune disorders, such as rheumatoid arthritis and type 1 diabetes. This suggests that it could be used as a biomarker for these conditions as well.

Conclusion

In conclusion, DUXA is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to be expressed and processed by the immune system makes it an attractive candidate for use as a biomarker for these conditions. Further research is needed to fully understand the role of DUXA as a drug target and biomarker.

Protein Name: Double Homeobox A

Functions: Transcription factor that acts as repressor

The "DUXA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DUXA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets